Caraco Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 12 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Profit -4.39%
(FY 2022)
- Ebitda -0.55%
(FY 2022)
- Net Worth -31.62%
(FY 2022)
- Total Assets 106.44%
(FY 2022)
About Caraco Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Jerry, Prince Elias, and Rakeshchandra Sinha serve as directors at the Company.
- CIN/LLPIN
U24100MH2012FTC225970
- Company No.
225970
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
12 Jan 2012
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Caraco Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakeshchandra Sinha  | Additional Director | 27-Feb-2024 | Current |
| Sanjay Jerry | Director | 28-Jan-2022 | Current |
| Prince Elias | Additional Director | 27-Feb-2024 | Current |
Financial Performance and Corporate Structure Insights of Caraco Pharmaceuticals.
Caraco Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 4.39% decrease in profit. The company's net worth observed a substantial decline by a decrease of 31.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Caraco Pharmaceuticals?
In 2023, Caraco Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sun Pharmaceutical Medicare LimitedActive 7 years 11 monthsPrince Elias and Rakeshchandra Sinha are mutual person
Pharmarack Technologies Private LimitedActive 9 years 2 monthsRakeshchandra Sinha is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Caraco Pharmaceuticals?
Unlock and access historical data on people associated with Caraco Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Caraco Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Caraco Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
